The rapid pace in the evolution of knowledge regarding how cancer develops and best approaches to treatment pose challenges to the medical community. This educational activity will review the deleterious effects of DNA damage, specifically the science of homologous recombination deficiency, and how it contributes to the development of cancer. Approved and expanded indications for the PARP inhibitors will be explained, including evidence for their use based on biomarkers, efficacy, and safety data. The activity will include real-life case scenarios demonstrating how genetic testing data can be used to develop treatment plans that illustrate these concepts.
Learning Objectives:
-Discuss the mechanisms of homologous recombination deficiency as they relate to the development of cancer.
-Apply evidence-based recommendations in parallel with genomic/molecular diagnostic testing results that inform the use of PARP inhibitors in treating cancer.
-Develop an interprofessional treatment plan taking into account patient-specific and cancer-specific factors, including biomarker testing data.
- Provider:American Society of Health-System Pharmacists
- Activity Link: https://elearning.ashp.org/
- Start Date: 2024-02-08 06:00:00
- End Date: 2024-02-08 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 32000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 32000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all